| アブストラクト | OBJECTIVE: The aim of this study was to assess the causality of anti-TNFalpha agents-associated pleuropericarditis in VigiBase with a focus on its diverse types. METHODS: All variables contained in the pleuropericarditis reports were reviewed. Well-documented reports, vigiGrade completeness score >/= 0.80 or with an informative narrative, were analyzed and with a focus on the clinical features of the cases. Bradford-Hill criteria were used in the case series assessment of causality. RESULTS: From 1968 up to 18 December 2019, there were 94 unique cases from 18 countries reporting pleuropericarditis with anti-TNFalpha agents as a suspected or interacting medicine. Among the 94 reports, 42 were identified as well-documented and further assessed for clinical features. Of the 42 cases, 39 were serious, including three fatal and seven life-threatening. In 35 cases, an anti-TNFalpha agent was the only suspected drug. Positive de- and re-challenge were reported in 95% and 17% of the 42 cases, respectively. The times to onset (TTO) varied greatly among individual cases, ranging from one month to 75 months (mean = 24 months). The most commonly involved anti-TNFalpha agents were adalimumab, infliximab and etanercept; and the mostly reported pleuropericarditis types were classified as autoimmune-related with (n = 17) or without (n = 15) co-reported drug-induced lupus (DIL), or infection-related (n = 8). While adalimumab was the most reported in the infection-related cases (7/8), infliximab was the most frequent in the autoimmune-related cases, in particular co-reported with DIL (9/17). There were four cases where the reaction occurred one to two months after the anti-TNFalpha agents (infliximab and adalimumab) were stopped. Based on the review of the case series using Bradford-Hill criteria the anti-TNFalpha agents associated pleuropericarditis are considered as a class effect. CONCLUSIONS: To clinically recognize and manage these potentially life-threatening serious cardiopulmonary complications, health care professionals should be aware of this possible risk. Meanwhile, attention should be paid to the clinical features of pleuropericarditis cases, since they may cause diagnostic and therapeutic difficulties. Considering the long elimination time, clinicians need to be reminded to remain vigilant for the adverse reactions even after discontinuing anti-TNFalpha therapy. |
|---|
| 組織名 | Department of Pharmacy, Xuan Wu Hospital, Capital Medical University, Beijing, PR;China.;Uppsala Monitoring Centre, Box 1051, Uppsala 75140, Sweden. Electronic address:;qun-ying.yue@who-umc.org. |
|---|
